NCT03278275View on ClinicalTrials.gov

PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

July 8, 2021

Study Completion Date

July 8, 2021

Conditions
Neuroendocrine Tumors
Interventions
DRUG

One injection of 68Ga-NOTA-AE105

One injection of 68Ga-NORA-AE105

DEVICE

PET/CT

Following injection of 68Ga-NOTA-AE105 the participants will be subjected to whole body PET/CT

Trial Locations (1)

2100

Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER

NCT03278275 - PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105 | Biotech Hunter | Biotech Hunter